SHIRE PLC: Director’s Share Dealings

Director's Share Dealings 
May 3, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that, following the
appointment of Flemming Ornskov, MD, to the Board of Shire plc as Chief
Executive Officer Designate on January 2, 2013 and in accordance with the terms
of his employment agreement, on May 2, 2013 Dr. Ornskov was conditionally
granted 15,286 deferred American Depository Shares ("ADSs") and a replacement
equity award under the Shire Portfolio Share Plan over 29,805 ADSs. 
The deferred ADSs represent approximately 75% of the replacement payment paid
to Dr. Ornskov as compensation for the sign-on bonus and annual bonus he
forfeited in connection with the termination of his prior employment. These
ADSs will be released on February 28, 2015, the second anniversary of the
originally planned date of grant of February 28, 2013, subject to Dr. Ornskov's
continued employment at the date of vesting. 
Dr. Ornskov's replacement equity award comprises Stock Appreciation Rights
("SARs") over 18,984 ADSs at an exercise price of $91.59 per ADS and
Performance Share Awards ("PSAs") over 10,821 ADSs. The SARs and PSAs will
normally vest on the third anniversary of the date of grant, subject to
performance targets being satisfied. No consideration was paid for the grant of
SARs and PSAs. 
Following this transaction, Dr. Ornskov holds awards of SARs, PSAs and deferred
shares over 124,893 ADSs. One ADS is equal to three Shire ordinary shares of 5
pence each. 
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a)
of the Disclosure and Transparency Rules. 
Tony Guthrie
Deputy Company Secretary 
For further information please contact: 
Investor Relations                                                              
Eric Rojas                         +1 781 482 0999    
Sarah Elton-Farr               +44 1256 894157    
Shire enables people with life-altering conditions to lead better lives. 
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs. 
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal,
Internal Medicine and Regenerative Medicine and we are developing treatments
for symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas. 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX 
Press Release                                      
-0- May/03/2013 13:45 GMT
Press spacebar to pause and continue. Press esc to stop.